$1.97
0.51%
Nasdaq, Aug 29, 11:40 pm CET
ISIN
US71880W2044
Symbol
PHIO

Phio Pharmaceuticals Corp. Stock price

$1.97
-0.57 22.44% 1M
+0.55 38.73% 6M
+0.17 9.44% YTD
-0.67 25.38% 1Y
-74.23 97.41% 3Y
-247.51 99.21% 5Y
-238,192.03 100.00% 10Y
-2,316,598.03 100.00% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.01 0.51%
ISIN
US71880W2044
Symbol
PHIO
Industry

Key metrics

Basic
Market capitalization
$11.3m
Enterprise Value
$500.0k
Net debt
positive
Cash
$10.8m
Shares outstanding
4.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
82.3%
Return on Equity
-151.4%
ROCE
-73.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-7.5m | $-8.4m
EBIT
$-7.4m | $-8.4m
Net Income
$-7.1m | $-8.8m
Free Cash Flow
$-7.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
14.7% | -13.6%
EBIT
15.3% | -13.2%
Net Income
18.3% | -23.2%
Free Cash Flow
21.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.5
FCF per Share
$-1.5
Short interest
7.6%
Employees
5
Rev per Employee
$0.0
Show more

Is Phio Pharmaceuticals Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Phio Pharmaceuticals Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Phio Pharmaceuticals Corp. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Phio Pharmaceuticals Corp. forecast:

Buy
86%
Hold
14%

Financial data from Phio Pharmaceuticals Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.86 3.86
1% 1%
-
- Research and Development Expense 3.59 3.59
26% 26%
-
-7.45 -7.45
15% 15%
-
- Depreciation and Amortization -0.01 -0.01
114% 114%
-
EBIT (Operating Income) EBIT -7.45 -7.45
15% 15%
-
Net Profit -7.09 -7.09
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about Phio Pharmaceuticals Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Head office United States
CEO Robert Bitterman
Employees 5
Founded 2011
Website phiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today